Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic334 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (308)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00406393 | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | completed | Phase 3 | 304 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT04629430 | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT(HCTDiet) | completed | N/A | 40 | University of VirginiaOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT00423514 | Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease | completed | Phase 1 / Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT03393611 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT00739141 | Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. | completed | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04866056 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | terminated | Phase 1 / Phase 2 | 1 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01272817 | Nonmyeloablative Allogeneic Transplant(Mini-allo) | completed | N/A | 36 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT01364363 | Unrelated Donor Stem Cell Transplantation | completed | N/A | 64 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT01685619 | AML-MDS Novel Prognostic Tests Clinical Study | completed | — | 11 | Nova Scotia Health AuthorityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT01586455 | Human Placental-Derived Stem Cell Transplantation(HPDSC) | completed | Phase 1 | 43 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01736683 | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Oct 24, 2022 | clinicaltrials |
| NCT01700673 | Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | completed | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02553941 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | completed | Phase 1 | 21 | Brian JonasOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT00053157 | Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia | completed | N/A | 10 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT03169296 | Clinical and Genomic Registry of MDS in Asia | unknown | — | 2,600 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04226768 | Enhanced Palliative Care in MDS and AML | unknown | N/A | 90 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02065154 | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | completed | Phase 2 | 39 | University of Alabama at BirminghamOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT02610777 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 120 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Sep 19, 2022 | clinicaltrials |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | completed | Phase 2 | 422 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01682226 | Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies | completed | Phase 2 | 84 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01168219 | Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01834248 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03434704 | Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole(SIR-POSA) | completed | Phase 2 | 10 | Ciceri FabioOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | terminated | Phase 2 | 123 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT02758223 | Prophylactic Application of Donor-derived TCM After Allogeneic HSCT(PACT) | completed | Phase 1 / Phase 2 | 16 | Wuerzburg University HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | active not recruiting | Phase 1 | 10 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02921802 | A Study of Special Use Results Surveillance of Revlimid 5mg Capsules | completed | — | 4,626 | CelgeneINDUSTRY | 1 | Jun 14, 2022 | clinicaltrials |
| NCT02452983 | Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome(SS1) | terminated | Phase 1 | 14 | Gustavo RiveroOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT03483324 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | completed | Phase 1 | 10 | Angiocrine BioscienceINDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer(HATCY) | terminated | Phase 3 | 63 | Kiadis PharmaINDUSTRY | 13 | May 24, 2022 | clinicaltrials |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | withdrawn | Phase 2 | 0 | Janssen Research & Development, LLCINDUSTRY | 11 | May 20, 2022 | clinicaltrials |
| NCT02979366 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 38 | Institut de Recherches Internationales ServierOTHER | 4 | May 18, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT00450450 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | completed | Phase 3 | 27 | Children's Oncology GroupNETWORK | 1 | Apr 28, 2022 | clinicaltrials |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | terminated | Phase 2 | 53 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03787498 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 22 | Opna Bio LLCINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02566395 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | completed | Phase 3 | 10 | Northwell HealthOTHER | 1 | Apr 7, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jan 4, 2023source: clinicaltrials